A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE).
Phase of Trial: Phase I/II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Carboplatin; Etoposide; Ifosfamide
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms BV-ICE
- 16 Sep 2019 Planned primary completion date changed from 15 Sep 2019 to 15 Sep 2020.
- 09 Nov 2018 Planned primary completion date changed from 15 Sep 2018 to 15 Sep 2019.
- 14 Sep 2017 Planned number of patients changed from 30 to 42.